Brief communication: The extent and determinants of viral suppression among patients on protease inhibitor-based Anti-retro-viral therapy undergoing intensive adherence counselling in a public HIV care center in Uganda.
Intensive adherence counselling
Mixed methods study
Protease inhibitors
Viral suppression
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
21
06
2024
accepted:
27
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Protease inhibitor (PI)-based Antiretroviral Therapy (ART) regimens are key drugs in HIV management, especially when used as second line drugs. However, some PI-based ART have high adherence demands or tolerable adverse effects which may affect adherence and subsequently viral suppression. We assessed the extent of viral suppression, its determinants, and the experiences of clients on PI-based ART undergoing intensive adherence counselling (IAC) in a public HIV clinic. Mixed methods sequential explanatory study involving a quantitative retrospective chart review for clients on PI-based ART who had received IAC from Dec 2016 to May 2023 and qualitative interviews for clients on PI-based ART who had received IAC in the past six months at an urban public HIV clinic in Uganda. In this study, a total of 189 client charts were included. The median number of IAC sessions received was three (interquartile range, IQR, of 3 to 4) with median time of receiving IAC of three ( IQR, of 2 to 4). One half (51%, 95/186) of the clients had achieved viral suppression and the odds of suppression increased by 30% for every additional month on IAC. Respondents perceived the effectiveness of PI-based ART and IAC in achieving and supporting viral suppression, respectively. Despite the perceived effectiveness of PI-based ART and IAC, suboptimal levels of viral suppression were observed among clients on PI-based ART who had received IAC. Therefore, it is important to provide IAC for optimal duration as it increases the chances of viral suppression. Further investigation of the barriers of viral suppression for clients on PI-based ART undergoing IAC is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Protease inhibitor (PI)-based Antiretroviral Therapy (ART) regimens are key drugs in HIV management, especially when used as second line drugs. However, some PI-based ART have high adherence demands or tolerable adverse effects which may affect adherence and subsequently viral suppression. We assessed the extent of viral suppression, its determinants, and the experiences of clients on PI-based ART undergoing intensive adherence counselling (IAC) in a public HIV clinic.
METHODS
METHODS
Mixed methods sequential explanatory study involving a quantitative retrospective chart review for clients on PI-based ART who had received IAC from Dec 2016 to May 2023 and qualitative interviews for clients on PI-based ART who had received IAC in the past six months at an urban public HIV clinic in Uganda.
RESULTS
RESULTS
In this study, a total of 189 client charts were included. The median number of IAC sessions received was three (interquartile range, IQR, of 3 to 4) with median time of receiving IAC of three ( IQR, of 2 to 4). One half (51%, 95/186) of the clients had achieved viral suppression and the odds of suppression increased by 30% for every additional month on IAC. Respondents perceived the effectiveness of PI-based ART and IAC in achieving and supporting viral suppression, respectively.
CONCLUSION
CONCLUSIONS
Despite the perceived effectiveness of PI-based ART and IAC, suboptimal levels of viral suppression were observed among clients on PI-based ART who had received IAC. Therefore, it is important to provide IAC for optimal duration as it increases the chances of viral suppression. Further investigation of the barriers of viral suppression for clients on PI-based ART undergoing IAC is needed.
Identifiants
pubmed: 39449062
doi: 10.1186/s12981-024-00661-0
pii: 10.1186/s12981-024-00661-0
doi:
Substances chimiques
HIV Protease Inhibitors
0
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Subventions
Organisme : Research Council
ID : MR/V03510X/1, MR/V030434/1
Informations de copyright
© 2024. The Author(s).
Références
Anderson J, Schiffer C, Lee S-K, Swanstrom R. Viral protease inhibitors. Antiviral Strategies. 2009:85–110.
Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-System Pharm. 1998;55(3):233–54.
doi: 10.1093/ajhp/55.3.233
Garone D, Conradie K, Patten G, Cornell M, Goemaere E, Kunene J, et al. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha. South Afr. 2013;14(4):170–5.
Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. Aids. 2005;19(18):2109–16.
doi: 10.1097/01.aids.0000194808.20035.c1
pubmed: 16284460
Mutumba M, Musiime V, Lepkwoski JM, Harper GW, Snow RC, Resnicow K, et al. Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV. AIDS Care. 2016;28(7):807–15.
doi: 10.1080/09540121.2015.1131966
pubmed: 27294696
Cluver L, Shenderovich Y, Toska E, Rudgard WE, Zhou S, Orkin M, Clinic and care: associations with adolescent antiretroviral therapy adherence in a prospective cohort in South Africa. AIDS (, London et al. England). 2021;35(8):1263-71.
MoH. CONSOLIDATED GUIDELINES FOR PREVENTION AND TREATMENT OF HIV IN UGANDA. In: Health Mo, editor. 2016. p. 154.
WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016.
MoH. Consolidated guidelines for prevention and treatment of HIV in Uganda. 2016.
McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12(4):399–404.
doi: 10.1080/09540120050123792
pubmed: 11091772
Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. JAIDS J Acquir Immune Defic Syndr. 2013;64(1):74–8.
doi: 10.1097/QAI.0b013e31829f05ac
pubmed: 23774877
Granich R, Gupta S, Wollmers M, Ruffner M, Williams B. Modeling the HIV epidemic: why the 95-95-95 target and ART effectiveness parameters matter. Int J Virol AIDS. 2018;5(1).
Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: operational issues. PLoS ONE. 2019;14(2):e0211326.
doi: 10.1371/journal.pone.0211326
pubmed: 30721229
pmcid: 6363281
Gusdal AK, Obua C, Andualem T, Wahlström R, Tomson G, Peterson S, et al. Voices on adherence to ART in Ethiopia and Uganda: a matter of choice or simply not an option? AIDS Care. 2009;21(11):1381–7.
doi: 10.1080/09540120902883119
pubmed: 20024714
Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18(1):1–9.
doi: 10.1186/s12889-018-5964-x
Odokonyero T, Mwesigye F, Adong A, Mbowa S. Universal Health Coverage in Uganda: the critical health infrastructure, healthcare coverage and equity. 2017.
Biadgilign S, Reda AA, Deribew A, Amberbir A, Belachew T, Tiyou A et al. Knowledge and attitudes of caregivers of HIV-infected children toward antiretroviral treatment in Ethiopia. 2011;85(2):e89–94.
Skovdal M, Campbell C, Nhongo K, Nyamukapa C. Gregson SJTIjohp, management. Contextual and psychosocial influences on antiretroviral therapy adherence in rural Zimbabwe: towards a systematic framework for programme planners. 2011;26(3):296–318.
Marotta C, Lochoro P, Pizzol D, Putoto G, Mazzucco W, Saracino A, et al. Capacity assessment for provision of quality sexual reproductive health and HIV-integrated services in Karamoja, Uganda. Afr Health Sci. 2020;20(3):1053–65.
doi: 10.4314/ahs.v20i3.8
pubmed: 33402951
pmcid: 7751512
Uganda AIDS, Commision U. 2023 FACT SHEET – FACTS ON HIV AND AIDS IN UGANDA 2023 (Based on Data Ending 31st December 2022). 2023.
Lukyamuzi Z, Etajak S, Katairo T, Mukunya D, Tetui M, Ssenyonjo A, et al. Effect and implementation experience of intensive adherence counseling in a public HIV care center in Uganda: a mixed-methods study. BMC Infect Dis. 2021;21(1):1–15.
doi: 10.1186/s12879-021-06862-6
Malterud K, Siersma VD, Guassora ADJQ. Sample size in qualitative interview studies: guided by information power. 2016;26(13):1753–60.
Johnson MJ. The Medication Adherence Model: a guide for assessing medication taking. Res Theory Nurs Pract.2002 Fall;16(3):179–92. https://doi.org/10.1891/rtnp.16.3.179.53008 . PMID: 12472293.
Gutierrez RG, Stata. Wiley Interdisciplinary Reviews: Comput Stat. 2010;2(6):728–33.
doi: 10.1002/wics.116
Armat MR, Assarroudi A, Rad M. Inductive and deductive: ambiguous labels in qualitative content analysis. Qualitative Rep. 2018;23(1).
Friese S. Atlas. Ti 8 Windows-Inter-coder Agreement Analysis Copyright© 2020 by Atlas. Ti Scientific Software Development Gmbh, Berlin. All rights Reserved. Manual Version: 669.20200507. Updated for Program Version: 8.4. Ti Scientific Software Development Gmbh; 2020.
Bekhet AK, Zauszniewski JA. Methodological triangulation: an approach to understanding data. Nurse Res. 2012.
Estill J, Ford N, Salazar-Vizcaya L, Haas AD, Blaser N, Habiyambere V, et al. The need for second-line antiretroviral therapy in adults in sub-saharan Africa up to 2030: a mathematical modelling study. Lancet HIV. 2016;3(3):e132–9.
doi: 10.1016/S2352-3018(16)00016-3
pubmed: 26939736
pmcid: 5688234
Kikaire B, Ssemanda M, Asiimwe A, Nakanwagi M, Rwegyema T, Seruwagi G, et al. HIV viral load suppression following intensive adherence counseling among people living with HIV on treatment at military-managed health facilities in Uganda. Int J Infect Dis. 2021;112:45–51.
doi: 10.1016/j.ijid.2021.08.057
pubmed: 34481969
Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1–9.
doi: 10.1186/s12889-018-5964-x
Izudi J, Castelnuovo B, King R, Cattamanchi A. Impact of intensive adherence counseling on viral load suppression and mortality among people living with HIV in Kampala, Uganda: a regression discontinuity design. PLOS Global Public Health. 2023;3(8):e0002240.
doi: 10.1371/journal.pgph.0002240
pubmed: 37549128
pmcid: 10406184
MoH. CONSOLIDATED GUIDELINES FOR PREVENTION AND TREATMENT OF HIV IN UGANDA. In: Health Mo, editor. Uganda2018.
Pius A, Josephine NN, Erick S, Winifred A, Rita M, Silverjoseph O, et al. Influence of intensified adherence counselling on viral load suppression of people receiving antiretroviral therapy at a health centre IV in southwestern Uganda: a qualitative study. AIDS Res Therapy. 2021;18(1):45.
doi: 10.1186/s12981-021-00372-w
De Clercq E. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv Pharmacol. 2013;67:317–58.
doi: 10.1016/B978-0-12-405880-4.00009-3
pubmed: 23886005